Rejbinder Kaur

The Discovery of I-BET726 (GSK1324726A), a Potent Tetrahydroquinoline ApoA1 Up-Regulator and Selective BET Bromodomain Inhibitor

Romain Gosmini, Van Loc Nguyen, Jérôme Toum et al. · Journal of Medicinal Chemistry · 2014 · 187 citations · Full text

Medicinal Chemistry, Histone Code, Drug Target +12

Targeting Gut T Cell Ca2+ Release-Activated Ca2+ Channels Inhibits T Cell Cytokine Production and T-Box Transcription Factor T-Bet in Inflammatory Bowel Disease

Antonio Di Sabatino, L. Rovedatti, Rejbinder Kaur et al. · The Journal of Immunology · 2009 · 104 citations · Full text

Inflammation, Cytokine, Autoimmune Disease +15

CCR2:  Characterization of the Antagonist Binding Site from a Combined Receptor Modeling/Mutagenesis Approach

Theo A. Berkhout, Frank E. Blaney, Angela Bridges et al. · Journal of Medicinal Chemistry · 2003 · 95 citations · Full text

Crystal Structure, Antagonist Binding Site, Drug Target +17

Pharmacokinetic profile of orexin A and effects on plasma insulin and glucagon in the rat

Marcus Ehrström, Erik Näslund, Fredrik Levin et al. · Regulatory Peptides · 2004 · 39 citations

Animal Physiology, Plasma Insulin, Biochemistry +11

Adaptive upregulation of gastric and hypothalamic ghrelin receptors and increased plasma ghrelin in a model of cancer chemotherapy-induced dyspepsia

N. M. Malik, Gary B.T. Moore, Rejbinder Kaur et al. · Regulatory Peptides · 2008 · 27 citations

Plasma Ghrelin, Medicine, Physiology +5